Johnson & Johnson

New Capabilities

Developer and commercial partner for ICOTYDE

For two decades, treating moderate-to-severe psoriasis required needles — self-injected drugs or clinic infusions many patients refused or abandoned. On March 18, 2026, the FDA approved ICOTYDE, a once-daily pill that blocks the IL-23 receptor like injectable biologics. In trials of roughly 2,500 patients, about 70 percent achieved clear or almost clear skin at 16 weeks, with side effects within 1.1 percentage points of placebo.

Updated May 30

Rule Changes

Defendant; won reversal on implied covenant but owes damages for efforts breach

Delaware's courts rule on American corporate disputes. On January 12, 2026, the state's Supreme Court decided that when a merger agreement specifies a particular path to an earnout payment, courts won't rescue sellers who failed to negotiate alternatives.

Updated May 26